# Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

> **NCT06118788** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangzhou Bio-gene Technology Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BIOLOGICAL:** BG1805

## Key facts

- **NCT ID:** NCT06118788
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118788, "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06118788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*